8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Depression as a Risk Factor for Dementia and Alzheimer’s Disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Preventing the onset of dementia and Alzheimer’s disease (AD), improving the diagnosis, and slowing the progression of these diseases remain a challenge. The aim of this study was to elucidate the association between depression and dementia/AD and to identify possible relationships between these diseases and different sociodemographic and clinical features. In this regard, a case-control study was conducted in Spain in 2018–2019. The definition of a case was: A person ≥ 65 years old with dementia and/or AD and a score of 5–7 on the Global Deterioration Scale (GDS). The sample consisted of 125 controls; among the cases, 96 had dementia and 74 had AD. The predictor variables were depression, dyslipidemia, type 2 diabetes mellitus, and hypertension. The results showed that depression, diabetes mellitus, and older age were associated with an increased likelihood of developing AD, with an Odds Ratio (OR) of 12.9 (95% confidence interval (CI): 4.3–39.9), 2.8 (95% CI: 1.1–7.1) and 1.15 (95% CI: 1.1–1.2), respectively. Those subjects with treated dyslipidemia were less likely to develop AD (OR 0.47, 95% CI: 0.22–1.1). Therefore, depression and diabetes mellitus increase the risk of dementia, whereas treated dyslipidemia has been shown to reduce this risk.

          Related collections

          Most cited references80

          • Record: found
          • Abstract: found
          • Article: found

          Dementia prevention, intervention, and care

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

            The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious. Copyright © 2011. Published by Elsevier Inc.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2020 Alzheimer's disease facts and figures

              (2020)
                Bookmark

                Author and article information

                Journal
                Biomedicines
                Biomedicines
                biomedicines
                Biomedicines
                MDPI
                2227-9059
                28 October 2020
                November 2020
                : 8
                : 11
                : 457
                Affiliations
                [1 ]Maimónides Institute for Biomedical Research (IMIBIC), University of Córdoba, Reina Sofia University Hospital, 14004 Córdoba, Spain; n92cahav@ 123456uco.es (V.C.-H.); z92rosam@ 123456uco.es (M.R.-S.); pcarrera@ 123456uco.es (M.d.P.C.-G.)
                [2 ]Ciber Fragility and Healthy Aging (CIBERFES), 28001 Madrid, Spain
                [3 ]Experimental and Clinical Physiopathology Research Group, Department of Health Sciences, Faculty of Experimental and Health Sciences, University of Jaén, E-23071 Jaén, Spain
                Author notes
                [* ]Correspondence: mrich@ 123456uco.es ; Tel.: +34-69-542-4299
                Author information
                https://orcid.org/0000-0002-3928-0092
                https://orcid.org/0000-0003-3317-267X
                https://orcid.org/0000-0002-6146-4402
                https://orcid.org/0000-0001-6575-8240
                Article
                biomedicines-08-00457
                10.3390/biomedicines8110457
                7693751
                33126696
                9dd0462a-e314-4e1b-99d9-60cfe73c00fb
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 24 September 2020
                : 26 October 2020
                Categories
                Article

                dementia,alzheimer’s disease,depression,diabetes mellitus,type 2,dyslipidemias,hypertension

                Comments

                Comment on this article